论文部分内容阅读
腹膜种植是胃癌转移的重要途径,是导致术后复发和死亡的常见原因。为此作者前瞻性研究了日本Fukuoka、Kyushu大学医学院第二外科医院1987年2月至1988年11月收治的36例胃癌浸润浆膜并行根治性切除术的病人,应用链球菌减毒冻干制剂OK-432作免疫化疗后的腹膜复发和生存时间。病人和方法:将病人随机分为两组:B组,手术日静脉注射丝裂霉素（MMC）0.5mg/kg,术后第4周和3个月给药0.25mg/kg。此后18个月内每3个月给药0.25mg/kg。术后2周至18个月内予uFT（喃氟啶和尿嘧啶按1:4克分子比例混合）400mg 口服。A组,除按B组给药外,术毕予腹腔内注射（IP）OK-432 20 Klinische Ein-beiten（临床单位KE）,皮内注射5KE,术后18个月内
Peritoneal implantation is an important route of gastric cancer metastasis and is a common cause of postoperative recurrence and death. The authors prospectively studied 36 patients undergoing radical radical resection of gastric cancer infiltrated with plasma membrane from Fukuoka, Kyushu University School of Medicine Second Surgery Hospital from February 1987 to November 1988, using streptococcal attenuated lyophilization. Preparation OK-432 for peritoneal recurrence and survival time after immunochemotherapy. Patients and Methods: Patients were randomly divided into two groups: Group B, intravenous mitomycin C (MMC) 0.5 mg/kg on the day of surgery, and 0.25 mg/kg 4 weeks and 3 months postoperatively. 0.25 mg/kg was administered every 3 months for 18 months thereafter. Within 2 weeks to 18 months after surgery, uFT (tetraflumurine and uracil were mixed in a 1:4 molar ratio) 400 mg orally. In group A, in addition to group B administration, intraoperative peritoneal injection (IP) OK-432 20 Klinische Ein-beiten (clinical unit KE), intradermal injection of 5KE, 18 months after surgery